Intelerad Acquires PenRad Technologies
What You Should Know: – Today, Intelerad, a leading global provider of enterprise medical imaging solutions, announced its acquisition of PenRad, a software provider for […]
What You Should Know: – Today, Intelerad, a leading global provider of enterprise medical imaging solutions, announced its acquisition of PenRad, a software provider for […]
CancerIQ Co-Founders Feyi Olopade Ayodele & Olufunmilayo (Funmi) Olopade, MD What You Should Know: – CancerIQ, a Chicago-based platform powering early cancer detection and prevention across broad […]
Thomas Bock, M.D., Chief Executive Officer of Notable What You Should Know: – Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, […]
In closing its Grail acquisition before U.S. and European regulators sign off, Illumina is taking a chance the deal will pass regulatory muster. It’s a […]
Xilis is developing technology that creates a living model of a patient’s tumor, then applies artificial intelligence to determine the best drug or drug combinations […]
The Federal Trade Commission is opposing Illumina’s proposed $7.1 billion Grail acquisition, arguing that it will reduce competition for multi-cancer early detection tests. Illumina disagrees […]
In the latest episode of our Health Innovators series, Paul Tunnah speaks to Billy Boyle, co-founder and CEO of Owlstone Medical, one of the UK’s […]
The genomic test, known as Oncotype DX, can help predict whether women with certain forms of breast cancer will benefit from chemotherapy — and those […]
What You Should Know: – UK-based Biofidelity raises $12 million in Series A funding to accelerate the launch of disruptive cancer diagnostic technology. – The funding […]
Copyright © 2024 | WordPress Theme by MH Themes